A5008919218- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Parathyroid Disorders and Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Neuroendocrine Tumor Research Advances
- IgG4-Related and Inflammatory Diseases
- Lymphoma Diagnosis and Treatment
- Pancreatitis Pathology and Treatment
- Synthesis and Biological Activity
- Genomic variations and chromosomal abnormalities
- Acute Lymphoblastic Leukemia research
- Peripheral Neuropathies and Disorders
- Eosinophilic Disorders and Syndromes
- Sarcoidosis and Beryllium Toxicity Research
- HIV/AIDS drug development and treatment
- Dermatological and COVID-19 studies
- Protein Kinase Regulation and GTPase Signaling
- Obsessive-Compulsive Spectrum Disorders
Institute of Cancer Research
2021-2024
University of Calgary
2015-2024
Foothills Medical Centre
2024
Mayo Clinic in Arizona
2008-2023
Alberta Health Services
2019-2022
Huntsman Cancer Institute
2019
University of Utah
2019
Princess Margaret Cancer Centre
2010-2013
The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present a monoclonal gammopathy undetermined significance (MGUS)-like phenotype has been hypothesized, but methods to identify this subgroup are not standardized its clinical is properly validated.An algorithm having MGUS-like was developed on the basis percentages total bone marrow (BM) plasma cells (PC) clonal PC within BM compartment, determined at diagnosis using flow cytometry in 548 MGUS 2,011...
Abstract Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions relapses. This study aims to evaluate the outcomes in newly diagnosed transplant‐ineligible patients using bortezomib/lenalidomide‐based regimens Canadian real world as well their second line. The Myeloma Research Group Database (CMRG‐DB) national database with input from multiple Centres now up 8000 entered. A total 1980 transplant ineligible were...
Summary Autologous stem‐cell transplant has been widely used to treat patients with AL amyloidosis. However, transplant‐related mortality rates are high, and a recent randomized trial suggested that non‐transplant regimens produced comparable results less toxicity. In order define the role of patient selection in stem cell transplantation, we evaluated 78 consecutive amyloidosis transplanted at our centre. Transplant‐related occurred 11·5%. Complete haematological response organ were...
High-dose chemotherapy with autologous stem cell transplantation (ASCT) can achieve excellent clinical responses in patients POEMS syndrome (Jimenez Zepeda et al., Blood 2010;116:2403; Gertz Am J Hematol 2005;79:319-328; Gherardi Ann Neurol 1994;35:501-505; Gattinoni Nat Rev Immunol 2006;6:383-393; Salem 2009;182:2030-2040; Cancer Immunother 2010;59:341-353; Cell 2010;261:134-143). However, melphalan ASCT should be considered carefully due to its treatment-related morbidity (Vuckovic...
Immunoparesis and polyclonal immunoglobulin recovery have been recently described as common indicators of immune dysfunction in patients with multiple myeloma. In the present study, we aimed to assess impact immunoparesis at day-100 post autologous stem cell transplant (auto-SCT) on clinical outcomes. A total 302 were included for analysis immunoparesis, 197 evaluable evaluation. was observed 93.5% cases, 47% cases having 12 months auto-SCT. Median overall progression-free survival longer...
Abstract Recently, the occurrence of oligoclonal and monoclonal bands (OB/MB) unrelated to original clone has been reported in patients with multiple myeloma who undergo autologous stem cell transplant (ASCT) and/or receive treatment novel agents. The aim our study was assess impact OB/MB on overall (OS) progression-free survival (PFS) for MM undergoing single ASCT at institution. All consecutive documented from January 2000 December 2012 were evaluated. Ninety-nine (11.8%) developed day 100...
Optimal conditioning and graft-vs-host disease (GVHD) prophylaxis for hematopoietic cell transplantation (HCT) are unknown. Here, we report on outcomes after low toxicity, myeloablative consisting of fludarabine, busulfan, 4 Gy total body irradiation, in combination with thymoglobulin post-transplant methotrexate cyclosporine. We retrospectively studied 700 patients hematologic malignancies who received blood stem cells from 7 to 8/8 HLA-matched unrelated or related donors. Median follow-up...
Lenalidomide is an immunomodulatory agent that belongs to a family of IMiDs used treat multiple myeloma. Hypersensitivity and skin reactions are adverse effects lenalidomide may lead discontinuation its use for myeloma making them contraindicated other IMiD therapies. Desensitization protocols have been developed desensitize patients reaction rash. We report case series 5 undergoing slow desensitization protocol in outpatient cancer center setting. Four the five were able be successfully...
Summary Daratumumab (dara) has significantly altered the therapeutic landscape of multiple myeloma (MM), especially in relapsed setting. This study aimed to evaluate outcomes dara‐containing regimens Canadian real‐world setting among and refractory MM available within national Myeloma Research Group Database (CMRG‐DB). A total 583 patients who received dara‐based therapy second‐line or later treatment were included. After a median follow‐up 17.5 months, progression‐free survival (PFS)...
The purpose of this study is to describe the real-world multiple myeloma (MM) population in Alberta by examining patient/clinical characteristics and treatment landscape. A retrospective, observational was conducted using province-wide, administrative health data from Alberta, Canada evaluating newly diagnosed MM (NDMM) patients. Between 1 April 2011 31 March 2017, 1377 treated NDMM cases were identified. Of those, 328 (23.8%) received an autologous stem cell transplant (ASCT) within first...
Abstract Amyloid light chain (AL) amyloidosis is a rare and chronic bone marrow disorder. Existing claims data can be used to help understand the real‐world treatment patterns outcomes of this patient population. Various population‐based administrative databases in Alberta, Canada were queried from 2010 mid‐2019 identify cases AL amyloidosis. Baseline disease characteristics, sequencing pharmacologic therapies, overall survival, healthcare resource utilization evaluated. A total 215...
Amyloidosis is a rare protein misfolding disease caused by the accumulation of amyloid fibrils in various tissues and organs. There are different subtypes amyloidosis, with light chain (AL) amyloidosis being most common. notoriously difficult to diagnose because it clinically heterogeneous, no single test diagnostic for disease, diagnosis typically involves multiple specialists. Here, we propose an integrated, multidisciplinary algorithm efficiently diagnosing amyloidosis. Drawing on...
Although daratumumab-containing regimens improve multiple myeloma (MM) outcomes, recurrence is inevitable.We performed a retrospective study using the Canadian Myeloma Research Group Database to benchmark efficacy of carfilzomib- or pomalidomide-based therapies immediately following progression on daratumumab treatment.We identified 178 such patients; median number prior lines therapy was 3, 97% triple-class exposed, and 60% refractory. In our cohort, 75 received subsequent carfilzomib-based...
Lenalidomide is an important component of initial therapy in newly diagnosed multiple myeloma, either as maintenance post-autologous stem cell transplantation (ASCT) or first-line with dexamethasone for patients' ineligible ASCT (non-ASCT). This retrospective study investigated treatment patterns and outcomes ASCT-eligible -ineligible patients who relapsed after lenalidomide part therapy, based on data from the Canadian Myeloma Research Group Database treated between January 2007 April 2019....